Cogent Biosciences Inc

Cogent Biosciences Inc

COGT

Get informed when a big investor buys or sells

+ Follow
Market Cap$6.48B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Cogent Biosciences IncCogent Biosciences Inc-16.4--71%-0.5
$50.00

Target Price by Analysts

34% upsideCogent Biosciences Target Price DetailsTarget Price
$0.87

Current Fair Value

97.7% downside

Overvalued by 97.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$6.48 Billion
Enterprise Value$6.54 Billion
Dividend Yield$- (-)
Earnings per Share$-2.04
Beta0.34
Outstanding Shares171,005,468

Return

Return on Equity-70.85%ROE
Return on Assets-45.20%
Return on Invested Capital-50.18%

Valuation & Multiples

P/E Ratio-16.42P/E Ratio
PEG-52.78PEG
Price to Sales-Price to Sales
Price to Book Ratio12.44Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-16.82
Enterprise Value to Net Income-18
Total Debt to Enterprise0.04
Debt to Equity0.46Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 10, 2026
EPS Estimate
$-0.55
Average shareholder expectation
Revenue Estimate
$1,000
Average shareholder expectation

Next Earnings Call

Expected Date
November 6, 2026
EPS Estimate
$-0.57
Average shareholder expectation
Revenue Estimate
$750,000
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000 59.30%
Total Calls- 100.00%
Total Puts- 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %55.85% 219.79%
Total Invested$1.46B 79.68%
Investors Holding94 223.00%

ESG Score

No data

About Cogent Biosciences Inc

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently ...